Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Comprehensive Loss (Unaudited)

v3.21.2
Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2021
Jun. 30, 2020
Income Statement [Abstract]        
Revenue $ 100 $ 1 $ 151 $ 29
Operating expenses:        
Cost of revenue - sales 42 10 70 40
Research and development 1,508 1,264 2,853 3,199
Sales and marketing 795 582 1,471 2,445
General and administrative 2,345 2,365 4,789 5,277
Total costs and expenses 4,690 4,221 9,183 10,961
Operating loss (4,590) (4,220) (9,032) (10,932)
Gain (loss) on change in estimated fair value of contingent royalty obligation (37) (76) (117) 245
Finance expense, net (117) (119) (234) (231)
Foreign currency gain (loss) 2 5 (8) (3)
Net loss (4,742) (4,410) (9,391) (10,921)
Deemed dividends from warrant issuance (6,145)
Net loss attributable to common shareholders $ (4,742) $ (4,410) $ (15,536) $ (10,921)
Basic and diluted loss per common share:        
Net loss (in Dollars per share) $ (0.10) $ (0.15) $ (0.21) $ (0.38)
Net loss attributable to common shareholders (in Dollars per share) $ (0.10) $ (0.15) $ (0.34) $ (0.38)
Weighted average number of common shares outstanding, basic and diluted (in Shares) 47,732,674 28,846,881 45,493,776 28,832,296